Quiroga Díaz Ricardo, Esparza Arechiga Miguel, Batiza Reséndiz Víctor, Coronado López Oscar, Hernández Ayup Samuel, Martínez Cuervo Jesús
Hospital de Ginecología y Obstetricia de Monterrey, N. L. México.
Ginecol Obstet Mex. 2002 Nov;70:572-5.
To show the advantages of the use of vaginal misoprostol, a prostaglandine E1 analogue, in the prevention of the post-partum haemorrhage.
This was a prospective, observational, comparative study. The study included 400 patients with high risk of postpartum haemorrhage at our center between January 1999 and may 2001. Patients were divided in two groups. In group I (208 patients) misoprostol was used in a dose of 800 ugr and in group II (192 patients) in whom misoprostol was not used. Both groups were treated initially with our conventional oxytocin protocol. We evaluated the use of additional oxytocin or ergotamine, haemoglobin levels pre and post-partum, the amount of blood loss, and the need for blood transfusion or hysterectomy.
The need for additional oxytocin or ergotamine was reduced to less than 10% in group I when compared to group II; the drop in haemoglobin levels and the amount of blood loss were also less in group I (p: 0.03). In this group only one patient needed for blood transfusion and no patient needed hysterectomy. In group II six patients need a blood transfusion and there was the need for two hysterectomies.
The use of vaginal misoprostol is effective to control the postpartum bleeding, reducing the blood loss after birth in women with high risk of post-partum haemorrhage as well as the need for blood transfusion. It's use has mild side effects and is of low cost.
展示使用前列腺素E1类似物阴道米索前列醇预防产后出血的优势。
这是一项前瞻性、观察性、对比研究。该研究纳入了1999年1月至2001年5月在本中心有产后出血高风险的400例患者。患者被分为两组。第一组（208例患者）使用剂量为800微克的米索前列醇，第二组（192例患者）未使用米索前列醇。两组最初均采用我们的常规催产素方案治疗。我们评估了额外催产素或麦角胺的使用情况、产前和产后的血红蛋白水平、失血量以及输血或子宫切除术的需求。
与第二组相比，第一组额外使用催产素或麦角胺的需求降至不到10%；第一组血红蛋白水平的下降和失血量也较少（p：0.03）。在该组中，只有1例患者需要输血，没有患者需要子宫切除术。在第二组中，有6例患者需要输血，并且有2例需要进行子宫切除术。
使用阴道米索前列醇可有效控制产后出血，减少产后出血高风险女性产后的失血量以及输血需求。其使用副作用轻微且成本低。
